We recently compiled a list 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of the best biotech stocks under $20 is CytomX Therapeutics, Inc.
TheFly reported on January 20 that Piper Sandler raised the target price of CTMX from $6.50 to $10 and maintained an overweight rating. The company noted that initial Phase 1 data for varsetatug maseatecan in heavily pretreated metastatic colorectal cancer showed an overall response rate of 28%, a disease control rate of 94%, and a median PFS of 5.8 months. This quarter, updated data from approximately 100 patients across three treatment cohorts are expected to demonstrate possible dose-dependent benefit.
Likewise, on the same day, Barclays analyst Etzer Darout also raised his price target for CytomX Therapeutics, Inc. (NASDAQ: CTMX) from $6 to $8 and maintained an Overweight rating. The company cited an upcoming colorectal cancer report that offers an attractive risk-reward profile.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage biopharmaceutical company developing Probody therapeutics, a conditionally activated antibody prodrug designed to improve cancer targeting and reduce extra-tumor toxicity. Its pipeline includes innovative immuno-oncology and targeted therapies designed to improve the safety and efficacy of solid tumors and other serious diseases.
While we acknowledge CTMX’s potential as an investment, we believe certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that would also benefit greatly from Trump-era tariffs and homegrown trends, see our free report on AI stocks Best Short-Term Artificial Intelligence Stocks.
Read next: The 12 Best Multibagger Stocks to Buy in 2026 and the 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
